First, immunohistochemistry (IHC) assays were conducted on tissue microarrays (TMAs) to examine the expression levels of mTOR in PCa specimens derived from EA and AA patients, and specimens derived from prostate, breast, colon, and lung cancer patients. Here, MTOR is linked to lung cancer.